Bispecific antibodies targeting mutant RAS neoantigens

Jacqueline Douglass, Emily Han Chung Hsiue, Brian J. Mog, Michael S. Hwang, Sarah R. DiNapoli, Alexander H. Pearlman, Michelle S. Miller, Katharine M. Wright, P. Aitana Azurmendi, Qing Wang, Suman Paul, Annika Schaefer, Andrew D. Skora, Marco Dal Molin, Maximilian F. Konig, Qiang Liu, Evangeline Watson, Yana Li, Michael B. Murphy, Drew M. PardollChetan Bettegowda, Nickolas Papadopoulos, Sandra B. Gabelli, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou

Research output: Contribution to journalArticlepeer-review

Abstract

Mutations in the RAS oncogenes occur in multiple cancers, and ways to target these mutations has been the subject of intense research for decades. Most of these efforts are focused on conventional small-molecule drugs rather than antibody-based therapies because the RAS proteins are intracellular. Peptides derived from recurrent RAS mutations, G12V and Q61H/L/R, are presented on cancer cells in the context of two common human leukocyte antigen (HLA) alleles, HLA-A3 and HLA-A1, respectively. Using phage display, we isolated single-chain variable fragments (scFvs) specific for each of these mutant peptide-HLA complexes. The scFvs did not recognize the peptides derived from the wild-type form of RAS proteins or other related peptides. We then sought to develop an immunotherapeutic agent that was capable of killing cells presenting very low levels of these RAS-derived peptide-HLA complexes. Among many variations of bispecific antibodies tested, one particular format, the single-chain diabody (scDb), exhibited superior reactivity to cells expressing low levels of neoantigens. We converted the scFvs to this scDb format and demonstrated that they were capable of inducing T cell activation and killing of target cancer cells expressing endogenous levels of the mutant RAS proteins and cognate HLA alleles. CRISPR-mediated alterations of the HLA and RAS genes provided strong genetic evidence for the specificity of the scDbs. Thus, this approach could be applied to other common oncogenic mutations that are difficult to target by conventional means, allowing for more specific anticancer therapeutics.

Original languageEnglish (US)
Article numberabd5515
JournalScience Immunology
Volume6
Issue number57
DOIs
StatePublished - Mar 25 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Bispecific antibodies targeting mutant RAS neoantigens'. Together they form a unique fingerprint.

Cite this